Perioperative medicine & outcomes
Postoperative Outcomes Among Sodium-Glucose Cotransporter 2 Inhibitor Users
Main finding · Postoperative eKAResult — go to the resultOdds ratio 1.11 95% CI 1.05–1.17Authors' conclusion
Patients treated with SGLT2i had a small but significantly higher risk of postoperative eKA but lower risks of postoperative AKI and 30-day mortality.
Study context
- Population
- Adults undergoing inpatient surgery, Veterans Affairs Health Care System National Registry, 2014–2022before matching
- Participants
- 462,968 adults
- Comparison
- Preoperative long-term SGLT2i users vs nonusers
- SGLT2in = 7,439
- Controln = 33,489reference
- Outcome
- Rate of postoperative euglycemic ketoacidosis (eKA)
Methodological detailsmulticentre, propensity-matched (1:5)
- Multicentre
- Propensity-matched (1:5)
Main finding
Postoperative eKA
Odds ratio
1.11
95% CI 1.05–1.17
SGLT2i vs Control
OR 1.11 (95% CI 1.05–1.17)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | SGLT2i | Control | OR (95% CI) | |
|---|---|---|---|---|
| Perioperative AKISGLT2i use vs propensity-matched controls | 0.69 (0.62–0.78) | |||
| Mortality · 30 daysSGLT2i use vs propensity-matched controls | 1.1% | 1.6% | 0.70 (0.55–0.88) | |
| 0.512Odds ratio (log scale) |
Hospital LOS, patients with vs without euglycemic ketoacidosis (eKA)
Days
- Median LOS with eKA (IQR 3-10)
- 6
- Median LOS without eKA (IQR 2-6)
- 3
- Increase in median LOS with eKA
- 3
Original publication
Postoperative Outcomes Among Sodium-Glucose Cotransporter 2 Inhibitor Users. JAMA Surg. Published 1 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →